Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for rare dementia: experimental drug DNL593 enters human trials

NCT ID NCT05262023

Ongoing Disease control Sponsor: Denali Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called DNL593 in healthy volunteers and people with frontotemporal dementia (FTD), a rare brain disease that causes personality changes and memory loss. The trial aims to check if the drug is safe, how the body processes it, and whether it might help. It includes a small number of participants and an optional long-term follow-up.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
DNL593
What this could lead to
If successful, this could point toward a treatment that slows or manages frontotemporal dementia, a currently untreatable disease.
What could go wrong
This is an early-phase trial with only 85 participants, so results may not confirm effectiveness. The drug may cause side effects or fail to show benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FRONTOTEMPORAL DEMENTIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

frontotemporal dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FRONTOTEMPORAL DEMENTIA

Contacts and locations

Locations

  • ASST degli Spedali Civili di Brescia

    Brescia, Italy

  • Azienda Ospedaliera Cardinale G Panico

    Tricase, Italy

  • Azienda Ospedaliera Universitaria Careggi

    Florence, Italy

  • CHU Rouen

    Rouen, France

  • CHU Toulouse

    Toulouse, France

  • CHU de Nantes

    Nantes, France

  • Campus Neurológico Sénior

    Torres Vedras, Portugal

  • Erasmus University Medical Center

    Rotterdam, Netherlands

  • Faculdade de Medicina Da Universidade de São Paulo

    São Paulo, Brazil

  • Fakultni nemocnice v Motole

    Prague, Czechia

  • Grupo de Neurosicencias de la Universidad de Antioquia

    Medellín, Colombia

  • Hospital Clinic de Barcelona

    Barcelona, Barcelona, 8036, Spain

  • Hospital Universitario San Ignacio

    Bogotá, Colombia

  • Hospital Universitario Virgen del Rocio

    Seville, Sevilla, 41013, Spain

  • Hospital Universitario de Donostia

    Donostia / San Sebastian, Guipúzcoa, 20014, Spain

  • Hospital de Braga

    Braga, Portugal

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • IRCCS Istituto Auxologico Italiano

    Milan, Italy

  • Istanbul University Istanbul Medical Faculty

    Istanbul, Turkey (Türkiye)

  • John Hopkins University

    Baltimore, Maryland, 21218, United States

  • L2IP - Instituto de Pesquisas Clinicas LTDA

    Brasília, Brazil

  • Ondokuz Mayis University Hospital

    Samsun, Turkey (Türkiye)

  • Simbec Orion

    Merthyr Tydfil, Wales, CF48 4DR, United Kingdom

  • UZ Leuven

    Leuven, Belgium

  • University of Antwerp

    Antwerp, Belgium

  • University of California San Francisco

    San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.